1. Introduction {#sec1}
===============

As a group of endogenous small noncoding RNA molecules, microRNAs (miRNAs) have been implicated in a wide diversity of basic cellular function by downregulating the expression level of their target genes \[[@B1]\]. It has been well acknowledged that miRNAs are extensively involved in human cancer via regulation of various protooncogenes and tumor suppressor genes \[[@B2], [@B3]\]. They are generated in reliance on the precise coordination of miRNA processing machinery proteins. The global or specific deregulation of key genes in the miRNA biosynthesis pathway may influence regular production of mature miRNAs, thus leading to malignant transformation \[[@B4]--[@B6]\].

As an important component of miRNA processing genes, RAN gene encodes the ras-related nuclear protein, which is a unique member of the Ras superfamily of GTPases. It is an essential ingredient for the transportation of pre-miRNAs from the nucleus to the cytoplasm through the nuclear pore complex in a GTP-dependent manner \[[@B7], [@B8]\]. RAN is overexpressed in many cancer cell lines, including the stomach, colon, pancreas, lung, and ovarian cancer \[[@B9]--[@B11]\]. Moreover, RAN protein is also a well-known downstream modulator of the PI3K signaling pathway, which mediates cancer cell invasion and metastasis \[[@B12]\]. Therefore, the mutations in RAN gene are very likely to play a critical role in pathology-related changes to miRNA transport and expression and thus participate in tumor genesis and development.

Single nucleotide polymorphisms (SNPs) are the most common form of genetic variation in human genomes and also widely exist in the RAN gene. Currently, accumulating studies have explored the association between RAN SNPs and cancer risk. However, the results are conflicted. For instance, Ye et al. conducted a case-control study in Caucasian esophageal-cancer patients and found that the rs14035 polymorphism of RAN was associated with an increased disease risk in a recessive model (*P* = 0.011, OR = 1.99, 95%CI = 1.17 − 3.38) \[[@B13]\]. By contrast, some other researches reported no association between this SNP and the risk of bladder cancer, renal cell carcinoma, and lung cancer \[[@B14]--[@B16]\]. The discrepancy might result from the differences in cancer etiology, underlying molecular mechanism, and/or environmental exposure in different population \[[@B17]\]. Therefore, whether the polymorphisms in the RAN gene are cancer-related and how they affect the susceptibility to human cancer remain unclear.

In the present study, we performed a systematic review for the association of RAN SNPs with overall cancer risk. Meanwhile, a meta-analysis was conducted based on available data, aiming at clarifying the association between RAN SNPs and cancer susceptibility. The study may provide novel clues for the identification of miRNA-related genetic biomarkers for the prediction of cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search {#sec2.1}
----------------------

Two investigators (Yanke Li and Fuqiang Zhang) independently performed publication search in the database of PubMed and Web of Science up to July 18, 2019, with the following key terms: 'RAN/Ras-related nuclear\', 'SNP/polymorphism/variant/variation\', and 'cancer/carcinoma/tumor/neoplasm\'. All retrieved articles were initially screened for eligible studies according to several standards: (1) case-control study and (2) focused on the association of RAN SNPs with cancer risk. The exclusion criteria contained (1) duplicate records and (2) records irrelevant to RAN SNPs or carcinoma (3) and with no available original data in the publications with authors failing to be contacted with.

2.2. Data Extraction {#sec2.2}
--------------------

The data was independently extracted by two investigators (Yanke Li and Fuqiang Zhang), and a consensus was reached concerning all items. The information obtained from each article consisted of the first author, publication year, country and ethnicity, sample size, cancer type, SNP genotype distribution in the case and control groups, source of the control group, genotyping method, and adjustment factors. The ethnicity was classified into Asian and Caucasian. The source of controls was divided into hospital-based (HB) and population-based (PB) groups. Both cervical cancer and breast cancer were categorized as "hormone-responsive cancer" in stratified analysis. Bioinformatics function prediction was performed for all involved RAN SNPs using SNPinfo Web Server (<https://snpinfo.niehs.nih.gov>).

2.3. Methodology Quality Assessment {#sec2.3}
-----------------------------------

The methodology quality of all enrolled studies after initial screening was independently evaluated by two reviewers (Yanke Li and Fuqiang Zhang) by scoring them based on previous literature \[[@B18]--[@B20]\]. Six assessment items were referenced: representativeness of the case group, source of the control group, ascertainment of carcinoma, sample size, quality control of genotyping method, and Hardy-Weinberg equilibrium (HWE). The scores ranged from 0 to 10. The study was judged as eligible for meta-analysis when the quality score was not less than 5.

2.4. False-Positive Report Probability {#sec2.4}
--------------------------------------

The false-positive report probability (FPRP) was tested to assess the level of statistically significant associations. First, we calculated the statistic power of each association based on the number of observations, and reported ORs and *P* values by using the software NCSS-PASS version 11.0.7 (USA). Then, the FPRP values were figured out followed by the instructions reported in the previous research, and the association with FPRP \< 0.5 was considered as a noteworthy finding \[[@B21]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

The Chi-square test was adopted to evaluate the HWE of SNP genotype frequency distribution in the control group. The association of each SNP with cancer risk was analyzed by calculating the odds ratio (OR) and 95% confidence interval (95% CI). Chi-square-based *Q* statistic test was used to examine the interstudy heterogeneity (statistical significance set as *I*^2^ \> 50%). The results in the fixed-effect model were selected when no significant interstudy heterogeneity existed; otherwise, the random-effect model was employed. In addition, the dominant and recessive genetic models were defined as heterozygote+variant homozygote vs. wild homozygote and variant homozygote vs. heterozygote+wild homozygote, respectively. Publication bias was assessed using Begg\'s rank correlation and Egger\'s linear regression methods. Sensitivity analysis was performed to evaluate whether the pooled results could be robust to some outlying study. All the above-mentioned analyses were conducted by STATA 11.0 software (STATA Corp., College Station, TX, U.S.A.). *P* \< 0.05 was considered to be statistically significant for two-sided tests.

3. Results {#sec3}
==========

3.1. Characteristics of Eligible Studies {#sec3.1}
----------------------------------------

A total of 165 articles were retrieved through publication search after removing duplicate records. We excluded 148 articles by reading titles and abstracts: 92 were functional studies; 29 were review, meta-analyses, or case reports; 18 were not related to RAN SNPs; 5 were not related to carcinoma; and 4 were focused on cancer prognosis. Therefore, 17 studies were involved in our systematic review. Among them, 5 publications had no available original data, and we failed to contact with their authors. Finally, 12 case-control studies were included in our meta-analysis, consisting of 7662 cases and 9807 controls ([Figure 1](#fig1){ref-type="fig"}). The characteristics of eligible studies are presented in [Table 1](#tab1){ref-type="table"}. All of them met the quality assessment.

3.2. Characteristics of Involved RAN SNPs {#sec3.2}
-----------------------------------------

A total of four RAN SNPs were involved in the systematic review, including rs14035 C\>T, rs3803012 A\>G, rs3809142 C\>T, and rs7301722 C\>A. Their basic information and function prediction results are shown in [](#supplementary-material-1){ref-type="supplementary-material"}. The assessment items of SNP biological function mainly comprised of a transcription factor binding site (TFBS), miRNA binding site, RegPotential score, and Conservation score. [Table 2](#tab2){ref-type="table"} shows the genotype frequency distribution of all these SNPs. Several records were excluded from quantitative synthesis due to not being in accordance with HWE (*P*~HWE~ \< 0.05) or the limited number of some loci. Consequently, two SNPs were included in the final meta-analysis, which were RAN rs14035 and rs3803012 polymorphisms.

3.3. Quantitative Data Synthesis of the Association between RAN SNPs and Cancer Risk {#sec3.3}
------------------------------------------------------------------------------------

First, the association of RAN SNPs with overall cancer risk was evaluated by calculating pooled ORs, and both the rs14035 and rs3803012 polymorphisms were found to be associated with cancer risk ([Figure 2](#fig2){ref-type="fig"}). The variant CT genotype of rs14035 was linked to a decreased risk when compared with the wild-type CC (*P* = 0.035, OR = 0.85, 95%CI = 0.73 − 0.99). On the contrary, the variant types of rs3803012 conferred to an increased risk (GG vs. AA: *P* = 0.022, OR = 2.06, 95%CI = 1.11 − 3.83; GG vs. AG+AA: *P* = 0.022, OR = 2.06, 95%CI = 1.11 − 3.83, [Table 3](#tab3){ref-type="table"}).

Due to the interstudy heterogeneity, stratified analysis was subsequently performed based on ethnicity, cancer type, and source of controls. Both the rs14035 and rs3803012 polymorphisms also showed significant association with cancer risk in some specific subgroups. In HB population, the variant types of rs14035 could decrease overall cancer risk (CT vs. CC: *P* = 0.011, OR = 0.71, 95%CI = 0.54 − 0.93; CT+TT vs. CC: *P* = 0.009, OR = 0.71, 95%CI = 0.55 − 0.92; and T vs. C: *P* = 0.014, OR = 0.76, 95%CI = 0.61 − 0.95), while no remarkable association was shown in the opposite subgroup. Interestingly, the rs3803012 polymorphism could only elevate the risk in PB population rather than HB population (GG vs. AA: *P* = 0.015, OR = 2.47, 95%CI = 1.19 − 5.13; GG vs. AG+AA: *P* = 0.015, OR = 2.48, 95%CI = 1.19 − 5.14, [Table 3](#tab3){ref-type="table"}).

3.4. Sensitivity Analysis {#sec3.4}
-------------------------

Sensitivity analysis was conducted to estimate the influence of some individual study on pooled results by calculating the ORs before and after exclusion of a single article from meta-analysis in turn. No outlying study was observed to significantly change the pooled ORs after it was removed ([](#supplementary-material-1){ref-type="supplementary-material"}).

3.5. Publication Bias {#sec3.5}
---------------------

Furthermore, we evaluated the potential publication bias for all involved studies by using two test methods. No significant publication bias was demonstrated in any genetic model of studied RAN SNPs ([Table 4](#tab4){ref-type="table"}).

3.6. FPRP Analysis {#sec3.6}
------------------

To assess the level of positive findings in the meta-analysis, FPRP analysis was performed for all the eight significant associations. According to the published professional guide, studies of rare tumors or small initial studies of common tumors should probably have an FPRP value of 0.5 or above. Given that some estimates of the overall FPRP in the molecular epidemiology literature have been near 0.95, an FPRP value near 0.5 would represent a substantial improvement over the current practice \[[@B21], [@B22]\]. Now that this is the first report to integrate the association between RNA SNPs and cancer risk with relatively limited studies and sample size involved, we set 0.5 as the FPRP threshold. It was shown that several significant associations of the rs14035 polymorphism (prior probability = 0.25/0.1) could be noteworthy ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, a systematic review was conducted for the association of all published SNPs in the RAN gene with the risk of overall cancer. Based on that, a meta-analysis was performed for two highly studied polymorphisms (rs14035 C\>T and rs3803012 A\>G). The results showed that both the rs14035 and rs3803012 polymorphisms were associated with cancer risk in overall population and some specific subgroups. To our knowledge, it is the first time to make a comprehensive assessment for the research progress in this field and also the first meta-analysis of cancer-related RAN SNPs.

RAN rs14035 SNP, located in the 3′-UTR of the gene, has been widely investigated for its role in carcinogenesis. Although some individual studies reported no significant association between this polymorphism and cancer susceptibility, our meta-analysis suggested that it was linked to a decreased risk of overall cancer. That may result from the limited sample size, ethnic diversity of study population, and complicated environmental factors varied from each study \[[@B20]\]. Additionally, the significance of the rs14035 polymorphism with cancer risk was only presented in the HB group rather than the PB group in stratified analysis. The HB controls were mainly selected from the subjects seeking for physical examination in hospitals, which might have a higher educational level and conferred to the discrepancy. As a locus within the 3′-UTR of a miRNA machinery gene, the rs14035 polymorphism could be responsible for locally altered mRNA secondary structure. For example, 3′-UTR SNPs may lead to different secondary mRNA structures, interfering with RNA-binding proteins, and thus result in distinct allele-dependent differences in mRNA stability \[[@B23], [@B24]\]. Therefore, the SNPs located in the 3′-UTR of RAN may affect its expression by altering mRNA stability and subsequently participate in cancer genesis and development. In conclusion, the above-mentioned findings demonstrated that RAN rs14035 SNP has the potential to be predictive biomarkers for cancer risk in overall population or some specific subgroup. However, all the hypotheses about related mechanism need to be elucidated by further molecular experiments.

Similar to the rs14035 polymorphism, RAN rs3803012 SNP is also a hotspot 3′-UTR variation with potential biological function. It was suggested to be associated with an increased cancer risk in our study, which was generally consistent with previous research reports. Other than the possible roles, it may exert as a 3′-UTR locus such as rs14035, the A to G changing of rs3803012 might enhance the binding of hsa-miR-199a-3p to the 3′-UTR of RAN. MiR-199a-3p was reported to be a potential candidate for intervention in cancer \[[@B25]\], which was highly expressed in some tumor cells but significantly underexpressed in hepatocellular carcinoma (HCC) and bladder cancer \[[@B26]--[@B28]\]. Hence, it could be inferred that RAN rs3803012 G allele might influence the targeting of hsa-miR-199a-3p and lead to reduced expression of RAN mRNA in cancer cells, further affecting a variety of miRNA biological synthesis \[[@B17]\]. Moreover, the SNP function prediction results also indicated that the rs3803012 polymorphism was quite likely to play carcinogenic roles via miRNA-mediated ways. Notably, the association between it and overall cancer risk also showed some differences when stratified by the source of controls. Unlike RAN rs14035, however, the rs3803012 polymorphism contributed to increased disease risk only in the PB group rather than HB group. This phenomenon suggested that the source of controls should be considered as an important influencing factor in the related meta-analysis about this field. Overall, RAN rs3803012 SNP might also become useful biomarkers for predicting cancer risk in general or specific population. Still, further investigations are needed to explore involved molecular mechanism.

Other than the two highly studied polymorphisms mentioned above, another two RAN SNPs (rs3809142 and rs7301722) were also included in our review. However, the original researches referring to them were insufficient in making quantitative synthesis. They were only reported in a case-control study about breast cancer in Chinese women conducted by Jiang et al. The rs7301722 polymorphism was found to be associated with a decreased risk of breast cancer in a codominant model (AA vs. CC: *P* = 0.046, OR = 0.68, 95%CI = 0.47 − 0.99), while no association was observed between the variant types of rs3809142 and disease risk \[[@B29]\]. Both the two SNPs belonged to the promoter region of RAN, and our bioinformatics prediction suggested that they might influence TFBS. As a result, they may affect the expression level of RAN by modulating the transcription initiation site and then change the downstream process. Therefore, RAN rs3809142 and rs7301722 could also have the potential to be functional SNPs as well as biomarkers for cancer risk prediction. Nevertheless, more related studies are needed to be involved in a meta-analysis to clarify the exact association between the two SNPs and overall cancer risk.

It should be acknowledged that our study had some limitations. Foremost, although the meta-analysis has contained a relatively large sample size, the relevant studies remain limited to some extent. It is an emerging field concerning the association of RAN SNPs with cancer risk, and further investigations are request for an updated meta-analysis. In addition, several records without available original data were excluded from final analysis, which might cause publication bias a little.

In summary, we systematically reviewed the association of RAN SNPs with the risk of overall cancer. Furthermore, a meta-analysis was performed using all available data for two highly studied polymorphisms among them (rs14035 and rs3803012). The results showed that both of them were associated with cancer risk in overall population and some specific subgroups, suggesting that they could be potential predictive biomarkers for cancer risk. The study would provide novel clues for the identification of miRNA-related genetic biomarkers applied to predicting cancer susceptibility.
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![The flow chart of study selection for the meta-analysis.](DM2020-9026707.001){#fig1}

![The forest plots of the association between RAN SNPs and cancer risk in overall analysis: (a) the heterozygote model of rs14035 C\>T; (b) the variant homozygote model of rs3803012 A\>G; (c) the recessive model of rs3803012 A\>G.](DM2020-9026707.002){#fig2}

###### 

The characteristics of eligible studies.

  Ref. no.   Year   Country   Ethnicity   Sample size   Source of controls   Genotyping method   Adjustment factors                                   Quality score                                                                                                               Citation   
  ---------- ------ --------- ----------- ------------- -------------------- ------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ---------- ------------
  1          2008   America   Caucasian   746           746                  PB                  SNPlex assay                                         Age, gender, and smoking status                                                                                             8.5        \[[@B14]\]
  2          2008   America   Caucasian   279           278                  PB                  SNPlex technology                                    Age, gender, and smoking status                                                                                             7.5        \[[@B15]\]
  3          2010   Korea     Asian       100           100                  HB                  Sequenome mass spectrometry-based genotyping assay   NM                                                                                                                          7          \[[@B16]\]
  4          2012   China     Asian       560           560                  PB                  PCR-RFLP                                             Gender, age, drinking status, smoking status, and family history of cancer                                                  9.5        \[[@B30]\]
  5          2012   China     Asian       397           900                  PB                  TaqMan allelic discrimination assay                  Age, sex, smoking status, and alcohol status                                                                                9.5        \[[@B31]\]
  6          2013   China     Asian       1300          2688                 PB                  TaqMan allelic discrimination assay                  Age, sex, smoking status, and drinking status                                                                               9.5        \[[@B17]\]
  7          2013   China     Asian       1486          1549                 PB                  TaqMan allelic discrimination assay                  Age, age at menarche, menopausal status, and parity                                                                         9.5        \[[@B32]\]
  8          2013   China     Asian       1792          1867                 PB                  TaqMan OpenArray genotyping system/TaqMan assay      Age, age at menarche, and menopausal status                                                                                 10         \[[@B29]\]
  9          2015   Korea     Asian       408           400                  HB                  PCR-RFLP                                             Age, gender, hypertension, and diabetes mellitus                                                                            5          \[[@B33]\]
  10         2015   Poland    Caucasian   135           170                  HB                  TaqMan SNP genotyping assay                          NM                                                                                                                          5.5        \[[@B34]\]
  11         2016   Korea     Asian       147           229                  PB                  PCR-RFLP                                             Age, gender, hypertension, diabetes mellitus, drinking status, and smoking                                                  5.5        \[[@B35]\]
  12         2017   China     Asian       312           320                  HB                  TaqMan SNP genotyping assay                          Age, gender, smoking status, alcohol intake, hepatitis B/C virus infection, and fatty liver/nonalcoholic hepatitis status   7          \[[@B36]\]

Note: PB, population-based; HB, hospital-based; PCR-RFLP, in reaction-restriction fragment length polymorphism; NM, not mentioned.

###### 

The genotype frequency distribution of RAN SNPs in enrolled studies.

  Ref. no.         Year   Cancer type       SNP^a^           Sample size   Case   Control   *P* ~HWE~   Included in meta-analysis                                      
  ---------------- ------ ----------------- ---------------- ------------- ------ --------- ----------- --------------------------- --------- --------- ---- --------- -------
  1                2008   Bladder cancer    rs14035 C\>T     746           746    348       329         58                          318       351       63   *0.013*   No^b^
  2                2008   RCC               rs14035 C\>T     279           278    143       110         23                          129       125       24   0.415     Yes
  3                2010   Lung cancer       rs14035 C\>T     100           100    65        23          5                           52        33        5    0.937     Yes
  4                2012   HCC               rs14035 C\>T     560           560    376       160         24                          390       160       10   0.162     Yes
  rs3803012 A\>G   560    560               508              52            0      512       48          0                           0.289     Yes                      
  5                2012   HNC               rs3803012 A\>G   397           900    344       45          2                           799       91        2    0.725     Yes
  6                2013   HCC               rs3803012 A\>G   1300          2688   1158      95          3                           2450      227       1    0.066     Yes
  7                2013   Cervical cancer   rs3803012 A\>G   1486          1549   1325      141         5                           1397      129       3    0.990     Yes
  8                2013   Breast cancer     rs3809142 C\>T   1792          1867   602       232         28                          615       239       32   0.149     No^c^
  rs3803012 A\>G   1792   1867              766              92            12     772       107         5                           0.539     Yes                      
  rs7301722 C\>A   1792   1867              881              733           131    966       716         174                         *0.015*   No^b/c^                  
  9                2015   CRC               rs14035 C\>T     408           400    267       128         13                          233       150       17   0.240     Yes
  10               2015   Larynx cancer     rs14035 C\>T     135           170    73        32          5                           67        93        10   *0.002*   No^b^
  11               2016   HCC               rs14035 C\>T     147           229    98        42          7                           137       69        3    0.080     Yes
  12               2017   HCC               rs3803012 A\>G   312           320    250       56          6                           260       55        5    0.298     Yes

Note: RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; HNC, head and neck cancer; CRC, colorectal cancer; *P*~HWE~, Hardy-Weinberg equilibrium in the control group. ^a^Ancestral alleles were referenced in NCBI database. ^b^Excluded due to not being in accordance with HWE. ^c^Excluded due to the limited number of this locus. The results are in italics if *P* \< 0.05.

###### 

The meta-analysis of the association between RAN SNPs and cancer risk.

  SNP                           *N*   Heterozygote vs. wild homozygote   Variant homozygote vs. wild homozygote   Dominant model   Recessive model   Allelic model                                                                                                                       
  ----------------------------- ----- ---------------------------------- ---------------------------------------- ---------------- ----------------- ------------------- ------ ---------- ------------------ ------ ---------- ------------------- ------ ---------- ------------------ ------
  rs14035 C\>T                  5     *0.035*                            0.85 (0.73-0.99)                         16.6             0.520^a^          1.22 (0.67-2.24)    57.7   0.102      0.88 (0.76-1.03)   43.9   0.338^a^   1.31 (0.75-2.27)    50.6   0.452^a^   0.93 (0.76-1.13)   55.9
   Ethnicity                                                                                                                                                                                                                                                                             
    Asian                       4     0.086                              0.86 (0.72-1.02)                         35.3             0.425^a^          1.39 (0.62-3.15)    63.5   0.311^a^   0.87 (0.66-1.14)   55.6   0.293^a^   1.49 (0.71-3.15)    57.4   0.629^a^   0.94 (0.72-1.22)   65.1
    Caucasian                   1     0.196                              0.79 (0.56-1.13)                         NA               0.645             0.87 (0.47-1.61)    NA     0.203      0.81 (0.58-1.12)   NA     0.899      0.96 (0.53-1.75)    NA     0.299      0.87 (0.67-1.13)   NA
   Source of controls                                                                                                                                                                                                                                                                    
    HB                          2     *0.011*                            0.71 (0.54-0.93)                         0.0              0.273             0.70 (0.37-1.33)    0.0    *0.009*    0.71 (0.55-0.92)   0.0    0.472      0.79 (0.42-1.50)    0.0    *0.014*    0.76 (0.61-0.95)   0.0
    PB                          3     0.431                              0.93 (0.77-1.12)                         0.0              0.216^a^          1.72 (0.73-4.05)    66.7   0.892      0.99 (0.82-1.19)   18.7   0.153^a^   1.77 (0.81-3.89)    61.7   0.532      1.05 (0.90-1.22)   38.9
  rs3803012 A \> G              6     0.913                              1.01 (0.89-1.14)                         0.0              *0.022*           2.06 (1.11-3.83)    0.0    0.587      1.04 (0.91-1.17)   0.0    *0.022*    2.06 (1.11-3.83)    0.0    0.324      1.06 (0.94-1.20)   0.0
   Cancer type                                                                                                                                                                                                                                                                           
    HCC                         3     0.676                              0.96 (0.80-1.16)                         0.0              0.240             1.85 (0.66-5.16)    35.6   0.827      0.98 (0.81-1.18)   0.0    0.245      1.84 (0.66-5.12)    37.2   0.999      1.00 (0.84-1.19)   0.0
    Hormone-responsive cancer   2     0.940^a^                           1.01 (0.77-1.34)                         51.9             0.071             2.17 (0.94-5.05)    0.0    0.533      1.06 (0.88-1.28)   23.5   0.069      2.19 (0.94-5.08)    0.0    0.312      1.10 (0.92-1.31)   0.0
    HNC                         1     0.474                              1.15 (0.79-1.68)                         NA               0.400             2.32 (0.33-16.56)   NA     0.400      1.17 (0.81-1.70)   NA     0.409      2.29 (0.32-16.30)   NA     0.341      1.19 (0.83-1.70)   NA
   Source of controls                                                                                                                                                                                                                                                                    
    HB                          1     0.785                              1.06 (0.70-1.60)                         NA               0.717             1.25 (0.38-4.14)    NA     0.721      1.08 (0.72-1.60)   NA     0.729      1.24 (0.37-4.09)    NA     0.668      1.08 (0.76-1.55)   NA
    PB                          5     0.979                              1.00 (0.88-1.14)                         0.0              *0.015*           2.47 (1.19-5.13)    0.0    0.649      1.03 (0.90-1.18)   0.0    *0.015*    2.48 (1.19-5.14)    0.0    0.371      1.06 (0.93-1.20)   0.0

Note: ^a^*P* was calculated by the random model; OR, odds ratio; CI, confidence interval; NA, not available. The results are in italics if *P* \< 0.05.

###### 

Begg\'s and Egger\'s tests for publication bias.

  Comparison type                           Begg\'s test   Egger\'s test           
  ----------------------------------------- -------------- --------------- ------- -------
  rs14035 C\>T                                                                     
   Heterozygote vs. wild homozygote         0.73           0.462           -1.55   0.220
   Variant homozygote vs. wild homozygote   0.73           0.462           0.61    0.587
   Dominant model                           0.24           0.806           -1.09   0.354
   Recessive model                          0.73           0.462           0.74    0.513
   Allelic model                            0.24           0.806           -0.63   0.572
  rs3803012 A\>G                                                                   
   Heterozygote vs. wild homozygote         0.38           0.707           0.66    0.543
   Variant homozygote vs. wild homozygote   0.73           0.462           1.12    0.345
   Dominant model                           0.38           0.707           0.72    0.513
   Recessive model                          0.73           0.462           1.06    0.367
   Allelic model                            0.00           1.000           0.68    0.532

Note: The results are in italics if *P* \< 0.1.

###### 

FPRP values for the association between RAN SNPs and cancer risk.

  Genotype                  OR (95% CI)        *P*     Statistical power^a^   Prior probability^b^                             
  ------------------------- ------------------ ------- ---------------------- ---------------------- --------- ------- ------- -------
  rs14035 C\>T                                                                                                                 
   CT vs. CC (overall)      0.85 (0.73-0.99)   0.035   0.226                  *0.453*                0.633     0.940   0.994   0.999
   CT vs. CC (HB)           0.71 (0.54-0.93)   0.011   0.227                  *0.205*                *0.350*   0.830   0.980   0.998
   CT+TT vs. CC (HB)        0.71 (0.55-0.92)   0.009   0.233                  *0.171*                *0.301*   0.796   0.975   0.997
   T vs. C (HB)             0.76 (0.61-0.95)   0.014   0.300                  *0.199*                *0.341*   0.825   0.979   0.998
  rs3803012 A\>G                                                                                                               
   GG vs. AA (overall)      2.06 (1.11-3.83)   0.022   \<0.001                0.992                  0.996     1.000   1.000   1.000
   GG vs. AG+AA (overall)   2.06 (1.11-3.83)   0.022   \<0.001                0.992                  0.996     1.000   1.000   1.000
   GG vs. AA (PB)           2.47 (1.19-5.13)   0.015   \<0.001                0.988                  0.994     0.999   1.000   1.000
   GG vs. AG+AA (PB)        2.48 (1.19-5.14)   0.015   \<0.001                0.988                  0.994     0.999   1.000   1.000

Note: FPRP, false-positive report probability; OR, odds ratio; CI, confidence interval. ^a^The statistical power is calculated using the number of observations and ORs and *P* values. ^b^The results are in italics if FPRP \< 0.5.

[^1]: Academic Editor: Fabrizia Bamonti
